Truscreen Group (ASX:TRU) Research & Development: A$0.75 Mil (TTM As of Mar. 2025)


What is Truscreen Group Research & Development?

Truscreen Group ASX:TRU Research & Development is A$0.75 Mil as of Mar. 2025. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Truscreen Group's Research & Development for the six months ended in Mar. 2025 was A$0.38 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was A$0.75 Mil.

Truscreen Group  (ASX:TRU) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Truscreen Group Research & Development Related Terms

Truscreen Group Research & Development Historical Data

* Premium members only.

The historical data trend for Truscreen Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Truscreen Group Research & Development Chart

Truscreen Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 0.80 0.81 0.74 0.77

Truscreen Group Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.31 0.36 0.38 0.00

Truscreen Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.75 Mil mean?
Truscreen Group (ASX:TRU) has a Research & Development of A$0.75 Mil as of Mar. 2025. Research and development expense is the total cost for research and development activities. View historical data on Truscreen Group and its competitors.
Is Truscreen Group's Research & Development too high?
Truscreen Group's current Research & Development is A$0.75 Mil.
How does Truscreen Group's Research & Development compare to ABT and SYK?
Truscreen Group's Research & Development of A$0.75 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Truscreen Group and its competitors. Truscreen Group's current Research & Development is A$0.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (ASX:TRU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 40% above its estimated fair value. The current Research & Development is A$0.75 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Truscreen Group (ASX:TRU), the current Research & Development is A$0.75 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Truscreen Group Business Description

Other Exchanges TRU:New Zealand
Address C/- HLB Mann Judd Limited, 57 Symonds Street, Level 6, Equitable House, Grafton, Auckland, NZL, 1010
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.